Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-19-016234
Filing Date
2019-08-19
Accepted
2019-08-19 09:47:35
Documents
74
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0619_bostontherapeutics.htm 10-Q 655803
2 UNWIND AGREEMENT BETWEEN BOSTON THERAPEUTICS, INC., CURE DM, INC. AND CURE DM GR f10q0619ex10-1_bostontherap.htm EX-10.1 90220
3 CERTIFICATION f10q0619ex31-1_bostontherap.htm EX-31.1 10495
4 CERTIFICATION f10q0619ex32-1_bostontherap.htm EX-32.1 3833
  Complete submission text file 0001213900-19-016234.txt   5457138

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE bthe-20190630.xml EX-101.INS 946569
6 XBRL SCHEMA FILE bthe-20190630.xsd EX-101.SCH 57717
7 XBRL CALCULATION FILE bthe-20190630_cal.xml EX-101.CAL 56203
8 XBRL DEFINITION FILE bthe-20190630_def.xml EX-101.DEF 340316
9 XBRL LABEL FILE bthe-20190630_lab.xml EX-101.LAB 478378
10 XBRL PRESENTATION FILE bthe-20190630_pre.xml EX-101.PRE 415887
Mailing Address 354 MERRIMACK STREET #4 LAWRENCE MA 01843
Business Address 354 MERRIMACK STREET #4 LAWRENCE MA 01843 (603) 935-9799
Boston Therapeutics, Inc. (Filer) CIK: 0001473579 (see all company filings)

EIN.: 270801073 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-54586 | Film No.: 191035295
SIC: 2834 Pharmaceutical Preparations